Neumora Therapeutics (NMRA)

Executive Summary

Neumora Therapeutics is a clinical-stage precision neuroscience company focused on developing data-driven therapeutics for neuropsychiatric and neurodegenerative disorders. Its lead asset, NMRA-335140, a kappa opioid receptor antagonist, is in Phase 3 trials for Major Depressive Disorder (MDD) with multiple studies ongoing. A completed Phase 2 trial showed positive signals, and the company is leveraging biomarker-based patient stratification to enhance trial success. Additionally, NMRA-335140 is being evaluated in a Phase 2 study for bipolar II depression, and early-stage asset NMRA-323511 targets Alzheimer's disease. With a market cap of ~$340 million, Neumora represents a high-risk, high-reward opportunity in CNS drug development.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 MDD Trial Data Readout (NCT06058013)50% success
• Q1 2026Phase 3 MDD Trial Data Readout (NCT06058039)50% success
• Q2 2026Phase 2 Bipolar II Depression Data (NCT06429722)40% success